Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.45 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231475 | 1.00 | CRBN (0.52) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL30689654 | 0.95 | IKZF2 (0.51) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL21759799 | 0.93 | CRBN (0.53) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL31748857 | 0.93 | CRBN (0.53) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL30906316 | 0.89 | CRBN (0.50) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL24186804 | 0.88 | CRBN (0.53) | CRBNCSNK1A1DDB1ALDH2 | |
| SCHEMBL30906224 | 0.88 | CRBN (0.49) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL25576779 | 0.88 | CRBN (0.49) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL20234420 | 0.87 | CRBN (0.49) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL29167295 | 0.87 | CRBN (0.52) | CRBNCSNK1A1IKZF2DDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4598905-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | University of Florida Research Foundation, Incorporated (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024162746-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | 한국화학연구원 | 2024-08-08 | — | — | WO | disclosed |
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885CSNK1A1 23/4885IKZF2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.